The newly launched Signa PET/MR Air device offers technological features that may bolster image quality and enhance diagnostic accuracy for diseases such as prostate cancer and Alzheimer’s disease.
Offering a variety of reported technological advances to facilitate the diagnosis of conditions such as Alzheimer’s disease and prostate cancer, the Signa PET/MR Air system (GE HealthCare) will be launched at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.
The Signa PET/MR Air system combines the high sensitivity of positron emission tomography (PET) with the anatomical precision offered by magnetic resonance imaging (MRI) in one device, according to GE HealthCare. The company said integrating prostate-specific membrane antigen (PSMA)-targeted PET radiotracer agents with the Signa PET/MR Air system may help optimize staging and facilitate a more precise diagnosis in prostate cancer cases.
GE HealthCare said integrating prostate-specific membrane antigen (PSMA)-targeted PET radiotracer agents with the newly launched Signa PET/MR Air system (shown above) may help optimize staging and facilitate a more precise diagnosis in prostate cancer cases. (Image courtesy of GE HealthCare)
Other features of the Signa PET/MR Air system include the Time-of-Flight (TOF) PET detector and MotionFree Brain PET. Addressing patient motion during exams without external tracking devices, MotionFree Brain PET enables consistent image quality, which reduces repeat scans and may potentially improve diagnostic accuracy for challenging patients, according to the company. GE HealthCare added that the sensitivity of the ToF PET detector can detect adverse effects in a single scan and provide insights into disease progression.
“Our latest PET/MR technology will directly impact the most challenging diseases, such as prostate cancer and Alzheimer’s disease. These diseases require precise and comprehensive imaging for accurate diagnosis, treatment planning, and therapy monitoring,” noted Jie Xue, president and CEO of MR at GE HealthCare. “We are excited to see SIGNA PET/MR AIR addressing these challenges and fulfilling our vision of providing access to advanced, personalized care.”
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.